China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou Smart Nuclide Pharmaceutical Technology Company, a move focused on the development of radioactive drugs based on conjugate technology.
Complementary Expertise in Radiopharmaceuticals
Under the terms of the partnership, Tot Bio will offer a comprehensive antibody conjugate development plan, leveraging its expertise in the field. Suzhou Smart Nuclide Pharma, equipped with a Class B radioisotope laboratory, will provide a complete radioisotope labeling development plan. This collaboration aims to expedite the development of innovative radioactive drugs based on conjugate technology and to jointly facilitate the commercialization of innovative achievements.
Nuclide Pharma’s Radiopharmaceutical Platform and Pipeline
Suzhou Smart Nuclide Pharma boasts a single-domain antibody radiopharmaceutical discovery, research and development, and production technology platform with independent intellectual property rights. The company’s product pipeline spans over 10 innovative nuclide diagnosis and treatment products, showcasing its commitment to advancing radiopharmaceuticals.
Tot Bio’s CDMO Solutions and Technological Edge
Tot Bio, on the other hand, prides itself on its expertise and technological advantages in the ADC core conjugate process and scale-up production. The company also has the independent analysis capability for ADC key quality attributes, enabling it to provide a one-stop CDMO solution for the localized production of antibodies to ADC raw solutions/formulations.-Fineline Info & Tech
